PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
16288018-5	2005	Enhanced expression of DDB2 improved repair of both CPDs and pyrimidine(6-4)pyrimidone photoproducts (6-4PP) in dermal fibroblasts.	pyrimidine(6-4)pyrimidone	61-86	damage specific DNA binding protein 2	Mus musculus	23-27
16288018-5	2005	Enhanced expression of DDB2 improved repair of both CPDs and pyrimidine(6-4)pyrimidone photoproducts (6-4PP) in dermal fibroblasts.	6-4pp	102-107	damage specific DNA binding protein 2	Mus musculus	23-27
16288018-9	2005	On the cellular level, we detected a delay in the repair of 6-4PPs in DDB2-/- dermal fibroblasts.	6-4pps	60-66	damage specific DNA binding protein 2	Mus musculus	70-74
12107171-7	2002	Significantly, overexpression of c-Abl increased tyrosine phosphorylation of DDB2 and suppressed UV-DDB activity.	Tyrosine	49-57	damage specific DNA binding protein 2	Mus musculus	77-81
12107171-8	2002	Conversely, a dominant negative, kinase-deficient allele of c-Abl decreased tyrosine phosphorylation of DDB2 and dramatically stimulated UV-DDB activity.	Tyrosine	76-84	damage specific DNA binding protein 2	Mus musculus	104-108
35428778-8	2022	Administration of pevonedistat to mice bearing HNSCC tumors significantly decreased DDB2 expression in tumor cells, increased DNA damage and potently enhanced the activity of cisplatin to yield tumor regression and long-term survival of all animals.	pevonedistat	18-30	damage specific DNA binding protein 2	Mus musculus	84-88
23604128-3	2014	We show that drug-induced resistance is a result of p53-dependent upregulation of the nucleotide excision repair (NER) genes xeroderma pigmentosum complementation group C (XPC) and damaged DNA-binding protein 2 (DDB2), which stimulate the repair of DNA interstrand cross-links (ICLs) arising from O(6)-chloroethylguanine.	o(6)-chloroethylguanine	297-320	damage specific DNA binding protein 2	Mus musculus	212-216
23604128-9	2014	Additionally, XPC and DDB2 induction occurred upon treatment with other cross-linking anticancer drugs, such as cisplatin and mafosfamide, indicating it is a general response of cancer cells to this group of chemotherapeutics.	Cisplatin	112-121	damage specific DNA binding protein 2	Mus musculus	22-26
23604128-9	2014	Additionally, XPC and DDB2 induction occurred upon treatment with other cross-linking anticancer drugs, such as cisplatin and mafosfamide, indicating it is a general response of cancer cells to this group of chemotherapeutics.	mafosfamide	126-137	damage specific DNA binding protein 2	Mus musculus	22-26